Do genes allow inflammation to kill or not to kill?

Journal of the American Society of Nephrology

Volumn 20, Issue 7, 2009, Pages 1429-1431

  Kovesdy, Csaba P ^a,b   Kalantar Zadeh, Kamyar ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 6;

ALLELE; ATHEROSCLEROTIC PLAQUE; CELL PROLIFERATION; DISEASE MARKER; DNA POLYMORPHISM; EDITORIAL; GENETIC ANALYSIS; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MORTALITY; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 67649703149     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009050510     Document Type: Editorial

References (15)

1. US Renal Data System: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
2. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
3. Kalantar-Zadeh K: Inflammatory marker mania in chronic kidney disease: Pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2: 872-875, 2007
4. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005
5. Zernecke A, Shagdarsuren E, Weber C: Chemokines in atherosclerosis: An update. Arterioscler Thromb Vasc Biol 28: 1897-1908, 2008
6. Bursill CA, Channon KM, Greaves DR: The role of chemokines in atherosclerosis: Recent evidence from experimental models and population genetics. Curr Opin Lipidol 15: 145-149, 2004 (Pubitemid 38453402)
7. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF: Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 271: 17161-17166, 1996 (Pubitemid 26244268)
8. Balistreri CR, Caruso C, Grimaldi MP, Listi F, Vasto S, Orlando V, Campagna AM, Lio D, Candore G: CCR5 receptor: Biologic and genetic implications in age-related diseases. Ann N Y Acad Sci 1100: 162-172, 2007 (Pubitemid 47092648)
9. Smith GD, Ebrahim S: Mendelian randomization: Prospects, potentials, and limitations. Int J Epidemiol 33: 30-42, 2004 (Pubitemid 38528650)
10. Pai JK, Kraft P, Cannuscio CC, Manson JE, Rexrode KM, Albert CM, Hunter D, Rimm EB: Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 186: 132-139, 2006
11. Muntinghe FLH, Verduin M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, Luttropp K, Nordfors L, Lindholm B, Brandenburg V, Schalling M, Stenvinkel P, Boeschoten EW, Krediet RT, Navis G, Dekker FW: CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 20: 1641-1649, 2009
12. Kovesdy CP, Kalantar-Zadeh K: Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs 17: 451-467, 2008 (Pubitemid 351578165)
13. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G: Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 19: 1507-1519, 2004 (Pubitemid 38796421)
14. Quinones MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, Willmon O, Kulkarni H, Reddick RL, Fernandes G, Kuziel WA, Ahuja SK, Ahuja SS: CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis 195: e92-e103, 2007 (Pubitemid 47561964)
15. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z: Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117: 1649-1657, 2008